drugset
drugset / Trial / NCT06966388

Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation

NCT06966388 ↗

Phase 1 Recruiting 33 enrolled Virginia Commonwealth University
NaSingle-groupOpen-labelSupportive care

Summary

This pilot study will evaluate the feasibility of at least twice daily use of azelaic acid in breast cancer patients undergoing radiation treatment.

Timeline

Start
2025-08-13
Primary completion
2027-11-30
Completion
2027-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Azelaic acid Small molecule — Topical

Indications

breast cancer